"ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΘΕΣΣΑΛΟΝΙΚΗΣ"

During the past decade, General Hospital of Thessaloniki "G. Papanikolaou" conducted 54 clinical trials. In the 10-year time frame, 54 clinical trials started and 25 clinical trials were completed, i.e. on average, 46.3% percent of trials that started reached the finish line to date. In the past 5 years, 32 clinical trials started and 16 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "General Hospital of Thessaloniki "G. Papanikolaou"" #1 sponsor was "Hoffmann-La Roche" with 11 trials, followed by "Boehringer Ingelheim" with 9 trials sponsored, "Celgene" with 8 trials sponsored, "Janssen Research & Development, LLC" with 7 trials sponsored and "George Papanicolaou Hospital" with 7 trials sponsored. Other sponsors include 31 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "General Hospital of Thessaloniki "G. Papanikolaou"" #1 collaborator was "George Papanicolaou Hospital" with 5 trials as a collaborator, "Eli Lilly and Company" with 4 trials as a collaborator, "Chugai Pharmaceutical" with 2 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator and "Pharmacyclics LLC." with 2 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "General Hospital of Thessaloniki "G. Papanikolaou"" are "Multiple Myeloma" (8 trials), "Idiopathic Pulmonary Fibrosis" (6 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Relapsed or Refractory Multiple Myeloma" (4 trials) and "Beta-Thalassemia" (3 trials). Many other conditions were trialed in "General Hospital of Thessaloniki "G. Papanikolaou"" in a lesser frequency.

Most popular intervention types in "General Hospital of Thessaloniki "G. Papanikolaou"" are "Drug" (68 trials), "Other" (5 trials), "Procedure" (3 trials), "Biological" (2 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Dexamethasone" (9 trials), "Bortezomib" (6 trials), "Lenalidomide" (6 trials) and "Daratumumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "General Hospital of Thessaloniki "G. Papanikolaou"" are 77 trials for "All" genders.

Currently, there are 30 active trials in "General Hospital of Thessaloniki "G. Papanikolaou"". 1 are not yet recruiting, 14 are recruiting, 14 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 35 completed trials in General Hospital of Thessaloniki "G. Papanikolaou", undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in General Hospital of Thessaloniki "G. Papanikolaou", 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 54 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 7 trials that are defined as “Not Applicable".